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Running title: Haptoglobin: point-of-care diagnostics for ovarian cancer 
 
ABSTRACT  
Objective: To investigate haptoglobin within ovarian cyst fluid (OCF) as a diagnostic 
biomarker for epithelial ovarian cancer (EOC) and develop an in vitro diagnostic point-of-
care device test (IVDPCT) for use in the operating theatre. 
Design: Retrospective and prospective cohort study 
Setting: South-East-Asia 
Population: Women with suspicious ovarian cysts 
Methods: Proteomic, immunohistochemical and ELISA methods measured haptoglobin in 
OCF to differentiate benign and EOCs. Diagnostic performance of haptoglobin was 
compared to CA125, Risk Malignancy Indices (RMI) and frozen section. Blinded validation of 
the IVDPCT was performed. 
Main outcome measures: Prediction of malignancy 
Results: In patients with benign cysts (n=87) haptoglobin concentration measured by ELISA 
was 0·70±0·09 mg/ml; early stage-EOC (n=17) was 6·22±0·53 mg/ml; and late stage-EOC 
(n=20) was 6·57±0·65 mg/ml. Haptoglobin in EOCs was significantly higher than benign 
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cysts (P<0·0001). Haptoglobin using rapid colorimetric assay (RCA) on a training set had 
sensitivity of 97·3% and specificity 92·0%, comparable to ELISA and frozen sections. The 
haptoglobin AUROC curve was 0·999 (95%CI 0·997-1·000) compared to 0·895 (95%CI 
0·814-0·977, P<0·05) for CA125. Haptoglobin performed significantly better than all the 
RMIs (P<0·01). Blinded validation studies showed a minor drop in average diagnostic 
performance (sensitivity 85·2% and specificity 90·5%) compared to training set. However, 
when compared to frozen section, haptoglobin was no worse in diagnostic accuracy for 
malignancy. 
Conclusion: Haptoglobin was identified as a biomarker for the detection of EOC with 
potential as a point-of-care diagnostic tool.  
Funding: This work was supported by the NUHS Cross Department Collaborative 
Grant, National Healthcare Group Small Innovative Grant, National Medical 
Research Council Clinician Scientists Award (CSA/007/2009, CSA/043/2012), 
SPRING, Singapore (Grant no:  TI/TECS/POV/11/15) and National University of 
Singapore. 
 
Keywords: epithelial ovarian cancer, in vitro diagnostic, biomarker, haptoglobin, point-of-
care, frozen section 
 
Tweetable abstract: Haptoglobin within ovarian cyst fluid: a biomarker for epithelial 
ovarian cancer and point-of-care diagnostics 
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INTRODUCTION   
Epithelial ovarian cancer (EOC) is a disease with poor prognosis. Lifetime risk of 
developing EOC is 1·4%, and worldwide 239,000 new cases are diagnosed 
annually.1 Two key factors that could improve survival in EOC are early diagnosis 
and appropriate primary surgery.2 Most patients are diagnosed at late stage (LS-
EOC), when the tumours respond poorly to therapy and have metastasised.3 
Consequently, five-year survival rates are only 40%.4 In contrast, patients diagnosed 
with early-stage EOC (ES-EOC) have 5-year survival rates >90%.5 There have been 
attempts to define symptoms that warrant earlier investigation, however, EOC 
symptom-complexes have low positive-predictive values (PPV) for ES-EOC6, and 
one in six ES-EOC patients are asymptomatic.7 No clinically-proven effective 
screening exists.8 There may be a role for a multimodal screening strategy4,9 
however, the value of screening in lowering mortality may only be realised after 
protracted close surveillance.4  
 
Benign ovarian cysts are common10 and the relative preponderance of cancers 
versus benign cysts vary.4,11,12 The natural history of cysts remains poorly 
understood.9,13 Laparoscopy or laparotomy is the standard surgical approach for 
benign ovarian masses,8 but in up to 14%, an unexpected malignancy is 
encountered.13 Preoperative prediction of the malignant potential remains 
challenging in early stage disease. This is especially true for ovarian masses 
identified in premenopausal women, and in South-East Asian countries where the 
incidence of EOC rises in the thirties.8,14-16 Intraoperative frozen section (FS) has 
been proposed to prevent delay in primary surgery,17 but suffers from several 
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limitations such as wide variation in accuracy due to large size of cysts, sampling 
error, and limitation of available staining methods owing to time constraints18,19  
 
Our pre-clinical exploratory proteomic studies demonstrated the presence of haptoglobin 
within the OCF which was able to differentiate between benign ovarian tumours, borderline 
and EOC (detailed in results and Appendix S1). As an acute phase reactant protein, serum 
haptoglobin concentrations rise in many cancers, but with poor sensitivities and specificities. 
In contrast, we showed through tissue microarray studies that haptoglobin within OCF 
accurately reflects the benign and malignant nature of the ovarian cystic masses since it is 
produced and concentrated locally within the cancer (detailed in results).  
 
We hypothesised that haptoglobin may be of potential use as an in vitro diagnostic tool with 
the development and validation of a clinical assay using retrospective and prospective 
clinical samples. 
 
MATERIALS AND METHODS  
Subject recruitment and sample collection 
We recruited 324 patients (Fig. 1A), between the ages of 11-74 years between December 
2003 and March 2014 undergoing either laparoscopy or laparotomy for clinically suspicious 
tumours of the ovary at our local academic medical centre (LMC) and from five hospitals in 
Indonesia and Vietnam (regional medical centres, RMCs).  
 
Our local academic medical centre recruited 284 patients (172 benign, 30 borderline and 82 
malignant tumours), a combination of retrospective and prospective cohorts. In our 
retrospective cohort, we collected and archived ovarian cyst fluid from 184 patients.  The 
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histopathology diagnoses (frozen section, when conducted, and paraffin) for the 184 
samples were known during selection for the type(s) of analysis that were performed. 
Retrospective sampling was performed to facilitate batch testing in laboratory investigations 
(preclinical and assay development phase). Prospective consecutive sampling was 
performed in 100 patients and analysed without any prior knowledge of the histopathology 
diagnosis (prospective validation phase). The RMC recruited 40 patients, and these samples 
were combined with our local retrospective cohort (31 benign tumours and 9 malignant 
tumours). In aggregate, they represented 17·9% of the whole retrospective cohort used.  
 
The National Healthcare Group Domain Specific Review Board approved local collection 
and use of patient samples, and the local ethics committee at each regional centre gave 
corresponding approval. All patients gave written informed consent. All tumours were 
defined by histopathological diagnoses (reference standard) and staging was according to 
the International Federation of Gynecology and Obstetrics (FIGO) staging for ovarian 
cancer.20 Ovarian dermoid cysts, endometriotic cysts, pelvic inflammatory disease, tubo-
ovarian abscesses, solid and frank malignant tumours were excluded from this study. 
 
Ovarian cyst fluid samples were collected either at laparoscopy or laparotomy without 
spillage into the abdominal cavity. At laparotomy, the intact cyst was removed from the 
abdominal cavity followed by immediate aspiration of cyst contents via a syringe. At 
laparoscopy, the cyst was contained within an endobag and aspiration of the cyst was 
performed either from the endobag before or after being removed from the abdominal cavity. 
OCF that were heavily contaminated with blood were excluded as they contain haptoglobin 
and haemoglobin, which would interfere with our haptoglobin-based test. Retrospective 
samples were transported on ice to the laboratory, centrifuged at 2,000 x g for 10 min at 4°C 
and the supernatant stored in -80°C until analysis. Prospective samples are kept on ice and 
analysed immediately, and not exceeding 4 hours post-cyst aspiration. 
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Measurement of haptoglobin concentrations by ELISA and rapid colorimetric assay 
(RCA) on retrospective samples 
The OCF haptoglobin concentrations were measured in benign tumours, and in ES- and LS-
EOCs using ELISA (Appendix S1) on 144 retrospective OCF samples (Fig. 1A). 
Histopathological classifications of all tumours (reference standard) and FIGO stages of 
malignant cases are detailed in Table S1 and S2. We used an RCA, and semi-quantitatively 
measured haptoglobin concentrations on the same retrospective cohort (Appendix S1). A 
receiver operating characteristic (ROC) curve was used to obtain haptoglobin cut-off 
concentrations (data not shown). 
 
Comparing OCF haptoglobin with CA125 and Risk of Malignancy Indices (RMIs) for 
prediction of malignancy 
Preoperative ultrasound reports and CA125 levels of patients recruited from LMC (Table S3) 
were obtained and evaluated for the risk of ovarian cancer by calculating three RMIs (RMI 
121, RMI 222 and, RMI 323; Appendix S1).  
 
Validation of OCF haptoglobin in blinded retrospective and prospective real-time 
samples 
We performed validation studies on 150 OCF samples (Fig. 1A, n=50 retrospective and 
n=100 prospective) in 96-well plate format (index test) (RCA) and IVDPCT format (index 
test) (RCA in IVDPCT; Development of IVDPCT- Appendix S1, Fig. S3) both in the 
laboratory and in the operating theatre (Appendix S1). The reference/gold standard for 
diagnosis of all tumours was tissue histopathology. Independent testers performed the index 
tests in the laboratory and operating theatre. The IVDPCT testers received training on 
IVDPCT use. Testers watched a training video of IVDPCT use followed by a live 
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demostration of the IVDPCT. Next, the testers performed practicals using the IVPCT with 
known haptoglobin controls.   
 
Statistical analysis  
We tested data for normality with D’Agostino’s K2 test, and evaluated statistical significance 
with Student t test (two-tailed) for comparison of age and peak intensity; Mann-Whitney U 
test (two-tailed) for comparison of serum CA125 level, tissue expression of haptoglobin, and 
OCF haptoglobin concentration; and Fisher’s exact test (two-tailed) or Pearson’s chi-square 
test for comparison of the proportions of patients present with each ultrasound feature or 
score between benign and malignant EOCs. We used ROC curves to assess the 
performance of biomarkers and evaluated the statistical significance for the comparison of 
two areas under the curve.24 We used nonparametric Spearman and Bland-Altman for RCA 
and IVDPCT correlation tests. All statistical analyses were performed using GraphPad Prism 
5.03 (GraphPad Software, La Jolla, CA, USA) and MedCalc v11.2.1.0 (MedCalc Software 
bvba, Mariakerke, Belgium). We expressed data as mean±S.E.M. and considered results 
statistically significant at P<0.05. 
RESULTS   
The results are presented in three phases: Preclinical Exploratory, Clinical Assay 
Development, and Prospective Validation studies.  
 
Preclinical Exploratory phase: we present results of haptoglobin, a potential 
biomarker within OCF, identified through proteomics (mass spectrometry, SDS-
PAGE, SELDI western blot) and immunocytochemical (tissue microarray) methods.  
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
We analysed retrospective OCF (Fig. 1A) from benign ovarian tumours, ES-EOCs 
and LS-EOCs with SELDI-TOF/MS in mass ranges 7-60 kDa and identified a high-
intensity discriminatory peak at 17.5 kDa that varied in proportion according to the 
extent of malignancy. It was present in 9/10 LS-EOCs, but absent/present at very 
low intensities in benign tumours. In early-stage disease, this peak was intermediate 
between benign and late-stage disease (Fig. S1A). Haptoglobin identity was 
confirmed by SDS-PAGE, peptide sequence matching, SELDI and western blot 
(Appendix S1; Fig. S1B-F; S2A,B).  
 
Using immunohistochemistry on tissue microarray (TMA) slides, we observed strong 
expression within the epithelial lining cells of EOC and absent/weak expression of 
haptoglobin in the epithelial linings of normal ovaries and benign ovarian cysts (Fig. 
S2C). These images were converted to grey-scale luminosity grading. Here we 
showed that cancerous cells had significantly higher levels of haptoglobin expression 
than seen in benign tumour cells (P<0.0001) (Fig. S2D), and borderline cells have 
intermediate staining.  
 
Clinical Assay Development phase: we present ELISA (quantitative) and rapid 
colorimetric assay (semi-quantitative) measurements of haptoglobin between benign, 
borderline, ES- and LS-EOCs. Result of operating characteristics of haptoglobin 
versus CA125 and RMI's is shown. Results of assay optimisation, observer bias 
study and reproducibility in 96-well plate and IVDPCT are presented. 
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Detection of OCF haptoglobin concentration by ELISA and RCA. 
The OCF haptoglobin concentration detected by ELISA in women with ES- or LS-EOC 
(6·22±0·53 mg/ml and 6·57±0·65 mg/ml, respectively, P>0·05) was significantly higher 
compared to that in women with benign tumours (0·70±0·09 mg/ml)(P<0·0001), although 
there was no significant difference in haptoglobin concentrations between ES-EOCs and LS-
EOCs (Fig. 1B). Amongst the women diagnosed with ES-EOC, five had serous carcinoma 
subtype (three low/intermediate-grade and two high-grade serous carcinoma (HGSC)). In all 
these samples, haptoglobin concentrations (range 3.9-7.3 mg/ml) were higher than the cut-
off value (2.85 mg/ml). The accuracy of RCA (at cut-off 0.5 mg/ml) was similar to that of 
ELISA (at cut-off 2.85 mg/ml) (Table 1) as determined using retrospective OCF samples 
(n=124; Fig. 1A, Table S1). Using an ELISA-based assay, haptoglobin has an overall 
sensitivity of 97·3% and NPV of 98·8% (Table 1). When considering only retrospective 
regional medical centre samples, in resource-challenged countries, the sensitivity and NPV 
are 88·9% and 96·9%, respectively. Using an RCA where the results could be ready in five 
minutes inside the operating theatre, the overall sensitivity and NPV were 97·3% and 98·8%, 
respectively (Table 1). Figure S4 demonstrates the appearance of the RCA in a 96-well 
plate.  
 
Of the 84 retrospective local academic medical centre cases, 33 women had FSs performed, 
with 16 benign and 17 cancerous cases as confirmed by histopathology. The overall 
accuracy in determination of the status of malignancy was 97·0% for cyst fluid haptoglobin 
determined by ELISA, 93·9% by RCA, and 90·9% for FS (Table 2A). Three cases (9·1%) 
had FS diagnosis discordant with the histopathology. There was one ES-EOC that FS 
misdiagnosed as benign (false negative), and two benign tumours misdiagnosed as 
borderline tumours (false positives). In contrast, in one case (3·0%) OCF haptoglobin 
measurements by ELISA and in two cases by RCA (6·1%) were discordant with 
histopathology. All discordant cases were benign tumours being over-diagnosed. Overall, 
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sensitivity, specificity, PPV and NPV of both methods of detecting OCF haptoglobin were 
similar to FS (Table 2A).  
 
OCF haptoglobin is more accurate than CA125 or RMIs. 
RMI is used frequently in the preoperative triage of patients with ovarian cysts. 
Menopause status is one key discriminant used in this risk calculation. In the 
Caucasian population, >80% of EOC patients are postmenopausal. In our local 
academic medical centre cohort, the mean ages for the benign and malignant groups 
were 39·6±13·9 and 51·5±10·0 respectively (P<0·0001), but 50% (14/28) of patients 
with cancer were premenopausal, which lead to lower RMI scores (Table S3). 
Another key component of the RMI is the CA125 concentration. In our cohort, ten 
percent of women with benign cysts had elevated CA125 concentrations and 14·3% 
of patients with malignant disease had a CA125<35 U/ml. Using a ROC curve 
analysis (Fig. 1C), we show that haptoglobin had superior diagnostic efficiency (AUC 
0·999, 95%CI 0·997-1·000) compared with CA125 (AUC 0·895, 95%CI 0·814-0·977; 
percentage∆=10·4%; P=0·013). Three versions of the RMI have been used, which 
are similar in principle (menopausal status, ultrasound features and CA125 
concentrations), but differ in the weights of each element: RMI 121, RMI 222 and, RMI 
323. Here too, haptoglobin out-performed all three RMIs (Fig. 1C).  
 
Assay optimisation, observer bias study and reproducibility in 96-well plate and 
IVDPCT 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
In the laboratory, we tested RCA in 96-well plates (Fig. S4) and IVDPCT formats 
(Fig. S3) using 50 retrospective samples (Fig. 1A, Table S5) where histopathology 
diagnoses were blinded to the testers (Appendix S1). The IVDPCT was in agreement 
with that of 96-well plate, as indicated by absorbance (630 nm) (Spearman's 
slope=1·25, R2=0·961; Bland-Altman (BA) bias= -0·08 (Fig. S5A,B)). There was no 
significant difference between the mean absorbance for the 96-well and for the 
IVDPCT (P>0·05; Table S4). There was no interobserver difference in the 
discrimination of visual colour appearance between the 96-well and IVDPCT (BA 
bias=0; Fig. S5C) and good agreement of visual calls compared to histopathology 
diagnoses (BA bias=0·01; Fig. S5D) with sensitivity of 100%, specificity 96·8%, PPV 
95%, and NPV 100% (Table 3). 
 
Prospective Validation phase: we present sensitivity, specificity, PPV and NPV results of 
100 prospective blinded OCF sample assayed in the laboratory and operating theatre.  
 
Fifty consecutive prospective blinded samples were collected at surgery for ovarian 
cyst and tested in the laboratory using the RCA (index test) (Fig. 1A) and compared 
to histopathology diagnosis (reference standard; Table S5).  We observed sensitivity 
of 85·7% (95%CI 62·6-96·2%), specificity of 89·7% (95%CI 71·5-97·3%), PPV of 
85·7% (95%CI 62·6-96·2%), and NPV of 89·7% (95%CI 71·5-97·3%)(Table 3).  
 
We followed this up with a prospective blinded study of the IVDPCT (index test) with 
50 OCF consecutively sampled and tested real-time (Fig. 1A) in the operation 
theatre with the IVDPCT tester blinded to the type of surgery performed and 
diagnosis. We recorded visual calls from the IVDPCT and compared to FS and 
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histopathology (reference standard obtained 1-2 weeks post-surgery; Table S5). The 
IVDPCT had sensitivity of 70% (95%CI: 35·4-91·9%), specificity of 85% (95%CI: 
69·5-93·8%), PPV of 53·8% (95%CI: 26·1-79·6%), and NPV of 91·9% (95%CI: 77-
97·9%)(Table 3). Of the 50 IVDPCT cases tested in theatre, 26 had FSs performed, 
with 22 benign and 4 cancerous cases as confirmed by histopathology. The overall 
accuracy in determination of the status of malignancy was 92·3% for IVDPCT 
compared to 88% for FS (Table 2B). Three cases (11·5%) had FS diagnosis 
incompatible with histopathology and one FS without a diagnosis due to technical 
difficulties during tissue cryosectioning (IVDPCT result matched histopathology). 
Three benign tumours were misdiagnosed: one low-grade neoplasm and two 
borderline tumours (false positives). In contrast, two cases (7·7%) by IVDPCT had 
OCF haptoglobin measurements discordant with histopathology. All discordant cases 
were benign tumours being over-diagnosed (false positives). Overall diagnostic 
performance was higher in IVDPCT when compared to FS (Table 2B).  
 
DISCUSSION  
Main findings  
We demonstrated the presence of haptoglobin in OCF of benign, borderline and 
malignant EOCs. The concentration of haptoglobin was significantly raised in ES and 
LS-EOC compared to benign tumours. We also observed raised haptoglobin 
concentrations in OCF of low-volume HGSC's.  
 
Semi-quantitative measurements of haptoglobin using a RCA in clinical assay 
development gave diagnostic accuracies similar to ELISA and frozen section. The 
haptoglobin AUROC curve was 0·999 (95%CI 0·997-1·000) compared to 0·895 
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(95%CI 0·814-0·977, P<0·05) for CA125. Haptoglobin performed significantly better 
than all the RMIs (P<0·01). We showed good correlation and between the RCA and 
IVDPCT and minimal intra- and inter-observer bias. 
 
In our prospective validation study, the diagnostic accuracy of IVDPCT was 
marginally poorer compared to that of the assay development tests, but it does 
maintain accuracy which is comparable to FS.  
 
Strengths and limitations 
Several studies exploring OCF for biomarker analysis found it to have little use for 
discriminating between benign and malignant tumours.25,26 One study suggested that 
OCF contained tumour-specific biomarkers,25 but this study had several limitations. 
The putative biomarkers identified by protein profiling were not confirmed by analysis 
of the exact peptide sequence; none of the peaks were superior to CA125 used 
alone; and a 1:1 ratio of benign versus malignant samples were used leading to a 
discovery strategy that would yield low PPVs.27 
 
We analysed haptoglobin concentrations in 324 OCF samples and haptoglobin is 
able to differentiate benign from malignant EOCs with high accuracy. Only 
haptoglobin within borderline ovarian tumour samples showed poorer diagnostic 
accuracy for malignancy when compared to FS, and haptoglobin's accuracy was 
only marginally better compared to CA125 or RMI1 (Table S2). A recent Cochrane 
review highlighted similar problems with the accuracy of frozen section in the 
diagnosis of borderline ovarian tumours.19 This validated our FS findings of poorer 
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accuracy (80%) in borderline ovarian tumours when compared to paraffin 
histopathology (Table S2). 
 
Tissue microarray study of 141 ovarian tissue samples showed haptoglobin 
accumulation within ovarian cyst fluid is more reflective of the biological changes 
within the tumour microenvironment. Although the pathophysiology of haptoglobin 
overexpression within malignant cysts remains unclear, we showed specific 
overexpression within the epithelial lining cells of cancerous cysts (Fig. S2C). While 
some investigators have shown presence of haptoglobin-1 precursor (HAP1) within 
ovarian cancer cells,28 other acute phase reactants have also been reportedly raised 
in HGSC's.29  
 
Unlike the RMIs, haptoglobin-based segregation for malignancy was independent of 
the patient’s menopausal status. Here, haptoglobin performed significantly better 
when compared with either CA125 used alone, or as part of the RMIs.  This is 
because in the western hemisphere, EOC is a disease mainly in the postmenopausal 
women.21 In contrast; half of the women with EOC in our study were premenopausal. 
This is in keeping with national data from Singapore (National Cancer Registry), and 
with our own hospital data collected over three years, suggesting an earlier rise in 
the incidence of EOC locally and regionally.14-16 The sensitivity of RMI1 for adnexal 
masses in this local hospital cohort of Asian patients is only 54%.  Recent use of the 
IOTA risk prediction model has shown a higher accuracy than RMI in both pre- and 
post-menopausal women, but still does not remove the need for intraoperative 
diagnostics in evaluation of suspicious ovarian tumours.30 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
EOC prevalence in our study ranged between 20% and 42%, which reflects clinical 
practice, as there are greater numbers of benign compared to malignant cases 
undergoing investigation. Even with the increased number of benign samples tested, 
haptoglobin gave high positive predictive values (PPV's) (range 83.7% to 94.7%) in 
all OCF samples. Typically, estimates of diagnostic performance in the validation 
samples are more realistic (and lower) than in the clinical assay development 
samples and this is seen in the lowered diagnostic performance of the validation 
samples. Due to the smaller sample size and lower prevalence of EOC, the 
confidence interval for the validation set is wider, compared to the assay 
development samples.  
 
Interpretation 
In our study, haptoglobin and FS seem to have comparable diagnostic accuracies. 
Sensitivity of FS varies between 65-97%, with specificities of 97-100% according to a 
meta-analysis.18 Factors contributing to this wide variation in accuracy include large 
size of cysts, sampling error, and limitation of available staining methods owing to 
time constraints.18,19 The overall utility of FS is even worse because of additional 
logistical limitations, and it can create inefficiencies in operating room utilisation with 
surgeries pausing for >30 minutes, increasing patient morbidity. Haptoglobin 
however, has the additional benefit of being a rapid, easy, and cost-efficient 
diagnostic test to perform at the patient's point-of-care. 
 
The IVDPCT is intended for use in women undergoing surgical investigation for a 
suspicious cystic mass, as a triage for FS, or even as a surrogate for FS in resource-
challenged countries where FS is not available. In a test with a high NPV, such as 
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this, if the IVDPCT were negative, we could avoid FS and complete the surgery; a 
true positive test would require either a FS or involvement of gynaecologic 
oncologists if FS were not readily available. Initial surgery performed by a 
gynaecologic oncologist is associated with accurate staging, complete resection of 
disease and improved patient prognosis.31,32  
 
Conclusion and research recommendations 
The present study is the first demonstration of OCF haptoglobin as a highly discriminatory 
biomarker between benign and malignant EOCs. Larger prospective blinded clinical studies 
are required to determine the operating characteristics of the IVDPCT in a relevant 
population to determine detection and false negative rates. Larger trials are also needed in 
identifying malignant cases and selecting benign cases that would not require FS evaluation. 
Our data suggests the potential utility of OCF haptoglobin as an in vitro diagnostic point-of-
care tool with accuracy comparable to frozen section. 
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TABLES 
Table 1 Clinical assay development: sensitivity, specificity, PPV and NPV of cyst fluid 
haptoglobin determined by ELISA and rapid colorimetric assay in the differential diagnosis of 
benign and malignant epithelial ovarian tumours in retrospective archived samples from 124 
women. 
 Local academic medical centre, N=84 
   
 Haptoglobin by ELISA* Haptoglobin by rapid colorimetric assay** 
 CA Non-CA Total CA Non-CA Total 
Test + 28 2 30 27 3 30 
Test - 0 54 54 1 53 54 
Total 28 56 84 28 56 84 
       
 Value 
(%) 
95% Confidence Interval  Value 
(%) 
95% Confidence Interval  
  Lower Upper  Lower Upper 
Sensitivity 100 85·0 100 96·4 79·8 99·8 
Specificity 96·4 86·6 99·4 94·6 84·2 98·6 
PPV 93·3 76·5 98·8 90·0 72·3 97·4 
NPV 100 91·7 100 98·1 88·8 99·9 
       
 Regional, N=40 
   
 Haptoglobin by ELISA* Haptoglobin by rapid colorimetric assay** 
 CA Non-CA Total CA Non-CA Total 
Test + 8 0 8 9 4 13 
Test - 1 31 32 0 27 27 
Total 9 31 40 9 31 40 
       
 Value 
(%) 
95% Confidence Interval  Value 
(%) 
95% Confidence Interval 
  Lower Upper  Lower Upper 
Sensitivity 88·9 50·7 99·4 100 62·9 100 
Specificity 100 86·3 100 87·1 69·2 95·8 
PPV 100 59·8 100 69·2 38·9 89·6 
NPV 96·9 82·0 99·8 100 84·5 100 
       
 Combined local and regional, N=124 
 
 Haptoglobin by ELISA* Haptoglobin by rapid colorimetric assay** 
 CA Non-CA Total CA Non-CA Total 
Test + 36 2 38 36 7 43 
Test - 1 85 86 1 80 81 
Total 37 87 124 37 87 124 
       
 Value 
(%) 
95% Confidence Interval  Value 
(%) 
95% Confidence Interval  
  Lower Upper  Lower Upper 
Sensitivity 97·3 84·2 99·9 97·3 84·2 99·9 
Specificity 97·7 91·1 99·6 92·0 83·6 96·4 
PPV 94·7 80·9 99·1 83·7 68·7 92·7 
NPV 98·8 92·8  99·9 98·8 92·4 99·9 
        *Haptoglobin at cut-off 2·85 mg/ml; ** Haptoglobin at cut-off 0·5 mg/ml. CA-Cancer; Non-CA Non-
Cancer; PPV - positive predictive value; NPV - negative predictive value 
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Table 2 Diagnostic accuracy of index test versus frozen section in clinic assay development and 
prospective validation phase. (A) Clinical assay development phase: ELISA, rapid colorimetric 
assay and frozen section compared to histology for the diagnosis of epithelial ovarian tumours in 
a subset of women (n=33) (B) Prospective validation (in operating theatre): IVDPCT and frozen 
section compared to histology for the diagnosis of epithelial ovarian tumours in a subset of 
women (n=26). 
A. Haptoglobin by ELISA* 
 
Haptoglobin by rapid 
colorimetric assay** 
Frozen section 
 CA Non-
CA 
Total CA Non-CA Total CA Non-CA Total
Test + 17 1 18 17 2 19 16 2 18 
Test - 0 15 15 0 14 14 1 14 15 
Total 17 16 33 17 16 33 17 16 33 
          
 Value 
(%) 
95% Confidence 
Interval (%) 
Value
(%) 
95% Confidence 
Interval (%) 
Value 
(%) 
95% Confidence 
Interval (%) 
 Lower Upper Lower Upper Lower Upper
          
Sensitivity 100 77·1 100 100 77·1 100 94·1 69·2 99·7 
Specificity 93·8 67·7 99·7 87·5 60·4 97·8 87·5 60·4 97·8 
PPV 94·4 70·6 99·7 89·5 65·5 98·2 88·9 63·9 98·1 
NPV 100 74·7 100 100 73·2 100 93·3 66·0 99·7 
Accuracy 97   93·9   90·9   
          
B.    IVDPCT in theatre
 
Frozen section 
    CA Non-CA Total CA Non-CA Total
          
   Test + 4 2 6 4 3 7 
   Test - 0 20 20 0 18 18 
   Total 4 22 26 4 21 25** 
          
    Value
(%) 
95% Confidence 
Interval (%) 
Value 
(%) 
95% Confidence 
Interval (%) 
    Lower Upper Lower Upper 
          
   Sensitivity 100·0 39·6 100·0 100·0 39.6 100·0 
   Specificity 90·9 69·4 98·4 85·7 62·6 96·2 
   PPV 66·7 24·1 94·0 57·1 20·2 88·2 
   NPV 100·0 80·0 100·0 100·0 78·1 100·0 
   Accuracy 92·3   88·0   
          
*Haptoglobin at cut-off 2·85 mg/ml; ** Haptoglobin at cut-off 0·5 mg/ml; PPV - positive predictive value; 
NPV - negative predictive value; IVDPCT - in vitro diagnostic point-of-care test device. 
**One FS did not provide a diagnosis due to technical difficulties during cryosectioning whereas IVDPCT 
and histology results were concordant. 
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Table 3 Sensitivity, specificity, PPV and NPV of cyst fluid haptoglobin determined by RCA and 
IVDPCT in the differential diagnosis of benign and malignant epithelial ovarian tumours in 150 
blinded samples (clinical assay development phase (n=50) and prospective validation phase 
(n=100)). 
 
    
 RCA (n=50) IVDPCT in lab (n=50) IVDPCT in theatre (n=50)
   
 CA Non-CA Total CA Non-CA Total CA Non-CA Total 
Test + 18 3 21 19 1 20 7 6 13 
Test - 3 26 29 0 30 30 3 34 37 
Total 21 29 50 19 31 50 10 40 50 
          
          
 Value 
(%) 
95% Confidence 
Interval (%) 
Value
(%) 
95% Confidence 
Interval (%) 
Value 
(%) 
95% Confidence 
Interval (%) 
 Lower Upper Lower Upper Lower Upper
          
Prevalence 42·0%   38·0%   20·0%   
Sensitivity 85·7% 62·6% 96·2% 100·0% 79·1% 100·0% 70·0% 35·4% 91·9%
Specificity 89·7% 71·5% 97·3% 96·8% 81·5% 99·8% 85·0% 69·5% 93·8%
PPV 85·7% 62·6% 96·2% 95·0% 73·1% 99·7% 53·8% 26·1% 79·6%
NPV 89·7% 71·5% 97·3% 100·0% 85·9% 100·0% 91·9% 77·0% 97·9%
Accuracy 88·0%   98·0%   82·0%   
Haptoglobin at cut-off 0·5 mg/ml; RCA-rapid colorimetric assay; IVDPCT-in vitro diagnostic point-of-care 
test device; CA-Cancer; Non-CA Non-Cancer; PPV-positive predictive value; NPV-negative predictive value 
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Figure 1. 
 
Figure 1 Haptoglobin levels are increased in ovarian cancer cyst fluid (CF). (A) Distribution and use of 
retrospective and prospective OCF samples for preclinical exploratory, clinical assay development 
and prospective validation study. (B) ELISA for ovarian cyst fluid (OCF) haptoglobin in 87 benign 
ovarian tumours, 17 early and 20 late stage ovarian cancers. Data are mean± S.E.M. *** P< 0·0001 
versus benign. ns=non-significance (P = 0·98). (C) ROC curve analysis showing the relationship 
between sensitivity and specificity for CF haptoglobin (blue line), serum CA125 (red line), RMI 1 
(green line), RMI 2 (purple line) and RMI 3 (orange line) in the discrimination between benign 
tumours (n = 50; six benign cases without serum CA125 information were excluded from ROC 
analysis) and ovarian cancers (n = 28). Haptoglobin performed better than CA125 (P = 0·013), RMI 1 
(AUC 0·879, 95% CI 0·793-0·966; P = 0·007), RMI 2 (AUC 0·906; 95% CI 0·843-0·970; P = 0·005) and 
RMI 3 (AUC 0·909, 95% CI 0·846-0·973; P = 0·006). At a haptoglobin cut-off level of 2·85 mg/ml the 
sensitivity was 97·3% (95% CI 84·2-99·9%), specificity was 97·7% (95% CI 91·1-99·6%), PPV was 94·7% 
(95% CI 80·9-99·1%) and NPV was 98·8% (95% CI 92·8-99·9%), at a prevalence of 3:2 benign to 
malignant cases. 
1A 
1B 1C 
